ClinicalTrials.gg
CompletedNCT03490097Updated Sep 20, 2018

Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination

A Phase 2/3 interventional study of Simvastatin 10mg and sofosbuvir plus daclatasvir in Chronic Hepatitis c and Metabolic Syndrome, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to male participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-09-20.

Sponsored by Ain Shams University · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2017, registered Mar 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Hepatitis C, Chronic with a site in Egypt — none open to participants now, 1 under way, 1 of them phase 3. Hepatitis C, Chronic · Egypt.

Enrollment
15th of 37
100 · median 94
Started
2017
with 3 others
Phase 2/3
6 of 46
none open now
Registered
32nd of 46
by date
Lead sponsor
6 of 46
Ain Shams University

Among the 46 studies in Hepatitis C, Chronic with a site in Egypt, this one is the 15th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2017, is one of 6 in phase 2/3, and was the 32nd registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 46 studies in Hepatitis C, Chronic with a site in Egypt is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 46 studies in Hepatitis C, Chronic with a site in Egypt as a file.
02

Study summary

The purpose of the study is to determine if statin can affect the clinical outcome of chronic hepatitis C patients receiving Sofosbuvir/Daclatasvir/Ribavirin combination

Read the detailed description

Aim of the work

To determine the benefits of statin use in CHC patients treated with Sofosbuvir/Daclatasvir/Ribavirin through :

Primary Outcome: Assessment of therapeutic SVR12

Seconadry Outcome

  1. assessment of Chronic hepatitis C(CHC) infection risk on development of metabolic syndrome through assessment of lipid profile , fasting glucose test , HgbA1C and C-reactive protein(CRP).

2- Evaluation of CHC related complications such as fibrosis and cirrhosis

Patients will be followed up for the whole study period and will be subjected to assessment of the following:

  1. CBC , liver function test , lipid profile and CK every month till the end of therapy.
  2. HgA1C and CRP at the end of therapy.
  3. HCV-PCR test 3 months after the end of therapy.
  4. Fibrosis using (FIB-4) 3 months after the end of therapy.
03

Conditions studied

  • Chronic Hepatitis c
  • Metabolic Syndrome
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male patients age 18 to 70 years old.
  2. Easy to treat group: treatment naïve patients with serum positivity by PCR.
  3. Clinically stable condition outpatients.
  4. count ≥ 150,000/mm³.
  5. ≤ 1.2.
  6. Serum albumin ≥ 3.5 g/dl.
  7. Total serum ≤ 1.2 mg/dl.

Exclusion criteria

Exclusion Criteria:

  1. Inadequately controlled diabetes mellitus ( > 9%) .
  2. Total serum > 3mg/dl.
  3. - co infection.
  4. -HCV co infection.
  5. Any cause for chronic liver disease other than hepatitis C
  6. Uncontrolled hypothyroidism.
  7. Hepatocellular carcinoma, except 4 weeks after intervention aiming at cure with no evidence of activity by dynamic imaging (CT or MRI).
  8. Extra-hepatic except after two years of disease-free interval.
  9. Child's C cirrhotic patients.
  10. Creatinine kinase > 350 u/l
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Group I

    low dose of simvastatin10 mg plus sofosbuvir 400mg / daclatasvir 60 mg daily for 12 weeks.

    Drug: Simvastatin 10mg · Drug: sofosbuvir plus daclatasvir

  • Active comparator
    Group II

    sofosbuvir plus daclatasvir

    Drug: sofosbuvir plus daclatasvir

Interventions

  • tablets

    Also known as: simvastatin

  • Drugsofosbuvir plus daclatasvir

    Drug pages: Sofosbuvir · Daclatasvir

    sofosbuvir 400mg daclatasvir 60 mg daily for 12 weeks.

    Also known as: Sovodac

06

What researchers measure

Primary outcomes

  1. SVR 12

    sustained virological response 3 months after the end of therapy

    Time frame: 3 months after end of therapy

Secondary outcomes

  1. Lipid marker

    lipid profile

    Time frame: three months

  2. Glycemic status marker

    fasting glucose test

    Time frame: three months

  3. inflammatory marker

    C-reactive protein(CRP).

    Time frame: three months

Other outcomes

  1. CHC related complications

    fibrosis and cirrhosis

    Time frame: 6 months

07

Study locations

1 site
  • Kobri El koba Armed Forces Hospital
    Cairo, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in May 2018, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2018
First posted
Apr 6, 2018
StartActual
Dec 1, 2017
Primary completionActual
May 23, 2018
CompletionActual
May 23, 2018
Last update
Sep 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03490097
Responsible party
Sara Mahmoud Shaheen (Associate Professor, Faculty of pharmacy, Ain Shams University, Ain Shams University) — Principal investigator
First posted
Apr 6, 2018
Start date
Dec 1, 2017
Primary completion
May 23, 2018
Completion
May 23, 2018
Last update
Sep 20, 2018

Study contacts

Nagwa Ali Sabri, Professor
study director · Professor of clinical pharmacy , ASU

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion